At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Paricalcitol (Zemplar)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
In Brief
A Phase 2 clinical trial evaluating Paricalcitol (Zemplar) for Pancreatic Cancer and 4 related conditions. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
CountriesUnited States
CollaboratorsBarts Cancer Institute, Abramson Cancer Center at Penn Medicine, Salk Institute for Biological Studies, Mayo Clinic, Princeton University, Imaging Endpoints, Translational Genomics Research Institute, Stand Up To Cancer, Cancer Research UK, Lustgarten Foundation, University of California, San Diego
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionDec 2023
TodayJul 2026
First PostedJan 30, 2018
Enrollment StartJan 31, 2018
Primary CompletionDec 11, 2023
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 8.4 years ago
Interventions
Paricalcitol (Zemplar)drug
combination therapy